18F-FDG PET/CT, 99mTc-MIBI, and MRI in Evaluation of Patients with Multiple Myeloma
- 16 January 2008
- journal article
- research article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 49 (2), 195-200
- https://doi.org/10.2967/jnumed.107.045641
Abstract
New imaging techniques have been introduced to assess the extent and severity of disease in multiple myeloma (MM) patients. The aim of our study was to compare newer imaging modalities -such as 18F-FDG PET/CT, 99mTc-methoxyisobutylisonitrile (99mTc-MIBI) scintigraphy, and MRI-to assess their relative contribution in the evaluation of MM patients at diagnosis. Methods:Thirty-three newly diagnosed patients with MM were prospectively studied. Diagnosis and staging were made according to standard criteria. All patients underwent whole-body 18F-FDG PET/CT, whole-body 99mTc-MIBI, and MRI of the spine and pelvis within 10 d, and imaging findings were compared. Results:18F-FDG PET/CT was positive in 32 patients (16 focal uptake, 3 diffuse uptake, 13 focal and diffuse uptake), 99mTc-MIBI was positive in 30 patients (6 focal, 11 diffuse, 13 focal and diffuse uptake),and MRI of the spine and pelvis was positive in 27 patients (6 focal, 13 diffuse, 8 focal and diffuse uptake). 18F-FDG PET/CT showed a total of 196 focal lesions (178 in bones and 18 in soft tissues), of which 121 were in districts other than the spine and pelvis, whereas 99mTc-MIBI visualized 63 focal lesions (60 in bones and 3 in soft tissues), of which 53 were in districts other than the spine and pelvis. In the spinal and pelvic regions, 18F-FDG PET/CT detected 75 focal lesions (35 in spine and 40 in pelvis), 99mTc-MIBI visualized 10 focal lesions (1 in spine and 9 in pelvis), and MRI detected 51 focal lesions (40 in spine and 11 in pelvis). Conclusion: In whole-body analysis, 18F-FDG PET/CT performed better than 99mTc-MIBI in the detection of focal lesions, whereas 99mTc-MIBI was superior in the visualization of diffuse disease. In the spine and pelvis, MRI was comparable to 18F-FDG PET/CT and 99mTc-MIBI in the detection of focal and diffuse disease, respectively. Because myelomatous lesions may often occur out of spinal and pelvic regions, MRI should be reserved to the evaluation of bone marrow involvement of these districts, whereas 18F-FDG PET/CT can significantly contribute to an accurate whole-body evaluation of MM patients. Finally, whole-body 99mTc-MIBI, despite its limited capacity in detecting focal lesions, may be an alternative option when a PET facility is not availableKeywords
This publication has 27 references indexed in Scilit:
- Technetium‐99m sestamibi scintigraphy is sensitive and specific for the staging and the follow‐up of patients with multiple myeloma: a multicentre study on 397 scansBritish Journal of Haematology, 2007
- The role of anatomic and functional staging in myeloma: Description of Durie/Salmon plus staging systemEuropean Journal Of Cancer, 2006
- Whole body MR imaging: Applications in oncologyEuropean Journal of Surgical Oncology, 2006
- Guidelines on the diagnosis and management of multiple myeloma 2005British Journal of Haematology, 2006
- Focal MIBI uptake is a better indicator of active myeloma than diffuse uptakeEuropean Journal of Haematology, 2005
- Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myelomaAnnals of Oncology, 2005
- Functional Imaging of Multidrug Resistant Phenotype by 99mTc-MIBI Scan in Patients with Multiple MyelomaCancer Biotherapy & Radiopharmaceuticals, 2004
- A comparison of fluorine‐18 fluoro‐deoxyglucose PET and technetium‐99m sestamibi in assessing patients with multiple myelomaEuropean Journal of Haematology, 2003
- Positron Emission Tomography (PET) for Staging of Solitary PlasmacytomaCancer Biotherapy & Radiopharmaceuticals, 2003
- Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma FoundationThe Hematology Journal, 2003